Skip to main content
Immunovia logo

Immunovia — Investor Relations & Filings

Ticker · IMMNOV ISIN · SE0006091997 LEI · 549300KHWL6KK1XGUO81 ST Human health and social work activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2025-08-27 Capital/Financing Update
Country SE Sweden
Listing ST IMMNOV

About Immunovia

https://immunovia.com/

Immunovia is a diagnostics company focused on revolutionizing the early detection of pancreatic cancer. Its primary product is the PancreaSure test, a simple blood test designed to detect pancreatic cancer at Stage 1 and 2 with high accuracy. The test is intended for annual surveillance of individuals at elevated risk due to family history or genetic mutations. PancreaSure functions by detecting proteins and other biomarkers indicative of pancreatic cancer growth. The company's mission is to improve survival rates for this highly lethal cancer by enabling diagnosis at its earliest, most treatable stages, offering a convenient alternative to invasive imaging procedures.

Recent filings

Filing Released Lang Actions
Immunovia genomför en företrädesemission om cirka 100 MSEK och säkrar brygglån
Capital/Financing Update Classification · 100% confidence The document is a press release from Immunovia AB announcing a rights issue (företrädesemission) of approximately 100 MSEK. It details the purpose of the capital raise, the subscription terms, the bridge loan, and the timeline for the issuance. This falls squarely under the definition of a capital/financing update, as it describes the company's fundraising activities and changes to its capital structure.
2025-08-27 Swedish
Immunovia carries out a rights issue of approximately SEK 100 million and secures bridge loans
Capital/Financing Update Classification · 100% confidence The document is a press release detailing a rights issue (capital raise) by Immunovia AB. It outlines the purpose of the funds (commercial launch of PancreaSure), the structure of the rights issue, subscription intentions, guarantee commitments, and the timeline for the Extraordinary General Meeting. This falls squarely under the definition of a capital/financing update.
2025-08-27 English
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from the Swedish Financial Supervisory Authority (Finansinspektionen) regarding a change in shareholding. It explicitly mentions 'Skäl för flaggning' (Reason for flagging) and details the percentage of shares held by Avanza Bank Holding AB in Immunovia AB. This is a classic 'flaggningsmeddelande' or major shareholding notification, which corresponds to the MRQ category.
2025-07-29 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 100% confidence The document is a 'flaggningsmeddelande' (flagging notification) filed with the Swedish Financial Supervisory Authority (Finansinspektionen). It details a change in shareholding where Avanza Bank Holding AB has crossed a 10% ownership threshold in Immunovia AB. This is a classic major shareholding notification, which corresponds to the 'Major Shareholding Notification' category.
2025-07-28 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage ('Innehavare', 'Andel', 'Aktier') for a specific entity ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension') related to the issuer ('Immunovia AB (publ)'). Key indicators are the transaction type ('Sälj' - Sell), the resulting shareholding percentage (9.94711%), and the context of reporting changes in significant ownership thresholds ('Gränsvärde för antal aktier 10 %'). This structure perfectly matches the definition of a Major Shareholding Notification, which reports when an investor crosses a threshold of significant ownership (usually 5%, 10%, etc.). This corresponds to the filing code MRQ (Major Shareholding Notification).
2025-06-24 Swedish
KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 14 MAJ 2025 I IMMUNOVIA AB (PUBL)
AGM Information Classification · 100% confidence The document is explicitly titled "KOMMUNIKÉ FRÅN ÅRSSTÄMMA DEN 14 MAJ 2025 I IMMUNOVIA AB (PUBL)" which translates to 'COMMUNIQUÉ FROM THE ANNUAL GENERAL MEETING ON MAY 14, 2025, IN IMMUNOVIA AB (PUBL)'. The content details the resolutions passed at the meeting, including approval of accounts, discharge of directors, election of board members and auditors, approval of the remuneration report, and crucially, decisions regarding new share/option programs. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2025-05-14 Swedish

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.